English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In a previously published study, we showed that expression of the  ABCD3  gene increased with increasing metastatic potential in a panel of prostate cancer cell lines derived from African American and Caucasian American men. Given importance of identifying biomarker(s) that can distinguish indolent versus aggressive prostate tumors, we conducted an immunohistochemical analysis of  ABCD3  expression Caucasian and African American prostate tumors.  ABCD3  expression in each patient population was compared with clinicopathologic characteristics, Gleason score, and age.  ABCD3  expression increased with increasing Gleason score ( P  = 0.0094), age ( P  = 0.0014), and pathology grade ( P  = 0.0007) in Caucasian patients. Interestingly, in the AA patients,  ABCD3  expression highly increased to the same degree in both low and high Gleason score tumors. Similarly,  ABCD3  expression was elevated to the same degree in BPH derived from AA. Our findings demonstrate that increased  ABCD3  expression correlates with Gleason Score in CA prostate tumors. However, in AA prostate tumors,  ABCD3  expression was higher and was sustained in both low Gleason and high Gleason AA tumors. While the functional role of  ABCD3  in prostate cancer is not completely elucidated, this gene warrants further study as a potential biomarker for aggressive prostate.

Immunohistological Analysis ofABCD3Expression in Caucasian and African American Prostate Tumors